Ondansetron-Claris Australia - English - Department of Health (Therapeutic Goods Administration)

ondansetron-claris

claris lifesciences australia pty ltd - ondansetron hydrochloride dihydrate -

MESNA-CLARIS mesna 200 mg/2 mL solution for injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

mesna-claris mesna 200 mg/2 ml solution for injection ampoule

baxter healthcare pty ltd - mesna, quantity: 100 mg/ml - injection, solution - excipient ingredients: disodium edetate; water for injections; nitrogen; sodium hydroxide - for the reduction and prevention of urinary tract toxicity (haemorrhagic cystitis) of oxazaphosphorines (see adverse effects sections of the cyclophosphamide and ifosfamide product information).

MESNA-CLARIS mesna 400 mg/4 mL solution for injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

mesna-claris mesna 400 mg/4 ml solution for injection ampoule

baxter healthcare pty ltd - mesna, quantity: 100 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; nitrogen; water for injections; disodium edetate - for the reduction and prevention of urinary tract toxicity (haemorrhagic cystitis) of oxazaphosphorines (see adverse effects sections of the cyclophosphamide and ifosfamide product information).

MESNA-CLARIS mesna 1000 mg/10 mL solution for injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

mesna-claris mesna 1000 mg/10 ml solution for injection ampoule

baxter healthcare pty ltd - mesna, quantity: 100 mg/ml - injection, solution - excipient ingredients: water for injections; nitrogen; sodium hydroxide; disodium edetate; benzyl alcohol - for the reduction and prevention of urinary tract toxicity (haemorrhagic cystitis) of oxazaphosphorines (see adverse effects sections of the cyclophosphamide and ifosfamide product information).